Illumina, Inc. (NASDAQ: ILMN) is a top-performing stock, surging 24.78% to $123.54 after beating earnings guidance for Q3 and projecting a smaller revenue decline for fiscal 2025. Net income dropped 79% to $150 million, with revenues remaining flat at $1.08 billion. CEO Jacob Thaysen credits revenue growth to clinical markets. The company now forecasts a revenue decline of 0.5% to 1.5% for fiscal 2025, down from the previous upper range of 2.5%. Illumina specializes in genomics and DNA sequencing technologies, serving life sciences, oncology, and reproductive health sectors. While ILMN shows investment potential, other AI stocks may offer higher returns with less risk. For more information, visit Insider Monkey for additional stock insights.

Read more at Yahoo Finance: Illumina (ILMN) Jumps 24.8% on Earnings Beat